Amisulpride: From animal pharmacology to therapeutic action

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 2, 1997, Pages

  Scatton, Bernard ^a   Claustre, Yves ^a   Cudennec, Annie ^a   Oblin, André ^a   Perrault, Ghislaine ^a   Sanger, David J ^a   Schoemaker, Hans ^a  

^a SANOFI   (France)

Author keywords

Benzamide; D3 receptors; Dopamine; Glucose use; Limbic system; Neuroleptics; Presynaptic dopamine autoreceptors

Indexed keywords

AMISULPRIDE; BENZAMIDE DERIVATIVE; DOPAMINE 3 RECEPTOR;

CONFERENCE PAPER; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; GLUCOSE TRANSPORT; HUMAN; LIMBIC SYSTEM; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030791026     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705002-00006     Document Type: Conference Paper

References (46)

1. Andreasen N, Rezai K, Alliger R, et al. (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiatry 49:943-958.
2. 2 Dopamine Receptor Interactions. Edited by Waddington J. London: Academic Press; pp 115-157.
3. Berman KF, Weinberger DR (1990) Prefrontal dopamine and defect symptoms in schizophrenia. In: Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Edited by Greden JF, Tandon R. London: American Psychiatry Press; pp 81-95.
4. Bischoff S (1992) Limbic selective neuroleptics. Clin Neuropharmacol 15 (suppl):265-266.
5. Boyer P, Lecrubier Y, Puech AJ, et al. (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72.
6. Carlsson A (1978) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135:164-173.
7. Carnoy P, Ravard S, Wemerman B, et al. (1986) Behavioural deficits induced by low doses of apomorphine in rats: evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs. Pharmacol Biochem Behav 25:503-509.
8. 3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol 7:105-109.
9. Costall B, Naylor RJ, Cannon JG, Lee T (1977) Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate-putamen. J Pharm Pharmacol 29:337-342.
10. Cudennec A, Jourdain D, Robert JP, et al. (1994) Effects of amisulpride (Solian®) on cerebral regional glucose use in the rat. Circ Métab Cerv 11:295-298.
11. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients: results of a double-blind study. Pharmacopsychiatry 23:125-130.
12. 3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology 124:231-240.
13. Di Chiara G, Porceddu ML, Vargiu L, et al. (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264:564-567.
14. Dolan RJ, Fletcher P, Frith CD, et al. (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378:180-182.
15. Dourish CT, Hutson PH (1985) Bilateral lesions of the striatum induced with 6-hydroxydopamine abolish apomorphine-induced yawning in rats. Neuropharmacology 24:1051-1055.
16. Dufour A, Desanti C (1989) Pharmacokinetics and metabolism of amisulpride. In: Amisulpride. Edited by Borenstein P. Paris: Expansion Scientifique Française; pp 43-51.
17. Ernst AM (1967) Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 10: 316-323.
18. Guyon A, Assouly-Besse F, Biala G, et al. (1993) Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats. Psychopharmacology 110:460-466.
19. Hillert A, Philipp M, Gattaz WF, et al. (1994) Amisulpride versus flupenthixol in the treatment of schizophrenia with predominant positive symptomatology: a controlled double-blind study [abstract]. Neuropsychopharmacology 10:31S.
20. Kahn RS, Davis KL (1995) New developments in dopamine and schizophrenia. In: Psychopharmacology: the Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York: Raven Press; pp 1193-1203.
21. Loo H, Poirier-Littre MF, Théron M, et al. (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18-22.
22. 2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124:154-158.
23. 3 receptors. Eur J Pharmacol 249:R5-R6.
24. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287.
25. 3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol 260: R3-R5.
26. Möller HJ, Boyer P, F'eurot O, Rein W, and the Prod-aslp Study Group (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison to haloperidol. Psychopharmacology (in press).
27. 1 antagonist SCH 23390. Psychopharmacology 82:409-410.
28. 3 receptor antisense influences dopamine synthesis in rat brain. NeuroReport 6:573-576.
29. Paillère-Martinot ML, Lecrubier Y, Martinot JL, et al. (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130-133.
30. 3 dopamine agonists in mice [abstract]. Behav Pharmacol 7 (suppl 1):83.
31. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82.
32. Puech A, Fleurot O, Rein W, et al. (1996) Amisulpride in the treatment of acute exacerbations of subchronic or chronic schizophrenia: a dose-range finding study [abstract]. Eur Psychiatry 11 (suppl 4):280S.
33. Ross CA, Pearlson GD (1996) Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach. Trends Neurosci 19:171-176.
34. Sanger DJ, Perrault G (1995) Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J Pharmacol Exp Ther 272:708-713.
35. 3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behav Pharmacol 7:477-482.
36. Scatton B (1982) Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. J Pharmacol Exp Ther 220:197-202.
37. 3 receptor antagonists [abstract]. Neuropsychopharmacology 10:242S.
38. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97.
39. 4. Neuropsychopharmacology 7:261-284.
40. 1) as a target for neuroleptics. Nature 347:146-151.
41. 3 dopamine receptor. Arzl Forsch Drug Res 42:224-230.
42. Suaud-Chagny MF, Ponec J, Gonon F (1991) Presynaptic antoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry. Neuroscience 45:641-652.
43. Van Wimersma Greidanus TB, Maigret C, Torn M, et al. (1989) Dopamine D-1 and D-2 receptor agonists and antagonists and neuropeptide-induced excessive grooming. Eur J Pharmacol 173:227-231.
44. Vasse M, Protais P, Costentin J, Schwartz JC (1985) Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunvn Schmiedebergs Arch Pharmacol 329:108-116.
45. Yamada K, Furukawa T (1980) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 67:39-43.
46. 1 dopamine receptor mediated behaviours in normal mice and in mice lesioned with 6-hydroxydopamine J Pharmacol Exp Ther 271:1462-1470.